Abstract
Parkinsonian-like state was generated in mice by the administration of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) to study the effects of Atremorine in Parkinson’s disease (PD) related neuropathology and behavior deficits. This devastating disease is caused by the progressive degeneration of dopaminergic neurons in the substantia nigra. Numerous therapeutic strategies have been developed to protect neuronal damage, although no effective treatment for PD has been validated yet. This study tested the preventive and therapeutic neuroprotective effect of Atremorine on MPTP parkinsonian mouse model. In addition to behavioral analysis, nigrostriatal dopaminergic neurons and inflammation biomarkers were directly quantified in the affected brain regions by specific antibody-antigen-binding methods. The affected neuronal populations and behavioural alterations induced by MPTP were significantly impaired in mice when treated with Atremorine-rich diet. Differences in the Atremorine content in diet induced some degrees of neuropathological and behavior therapeutical improvement, based on the progressive beneficial effects observed in nigro-striatal dopaminergic neurons of MPTPinduced mice. Data demonstrated that Atremorine promotes neuroprotection and behavior recovery in the injured MTPT-mouse brain by modulating the expression levels of tyrosine hydroxylase, glial proteins, apoptosis and endogenous dopamine and neuromelanin concentrations, probably the key to recover the basal ganglia function.
Keywords: Parkinson's disease, MPTP, neuroinflammation, neuroprotection, biotherapy, inflammation biomarkers.
Current Pharmaceutical Design
Title:Neuroprotective Effect of Atremorine in an Experimental Model of Parkinson’s Disease
Volume: 23 Issue: 18
Author(s): Ivan Carrera*, Lucia Fernandez-Novoa, Carolina Sampedro and Ramon Cacabelos
Affiliation:
- Health Biotechnology, EuroEspes Biotechnology, 15165 – Corunna,Spain
Keywords: Parkinson's disease, MPTP, neuroinflammation, neuroprotection, biotherapy, inflammation biomarkers.
Abstract: Parkinsonian-like state was generated in mice by the administration of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) to study the effects of Atremorine in Parkinson’s disease (PD) related neuropathology and behavior deficits. This devastating disease is caused by the progressive degeneration of dopaminergic neurons in the substantia nigra. Numerous therapeutic strategies have been developed to protect neuronal damage, although no effective treatment for PD has been validated yet. This study tested the preventive and therapeutic neuroprotective effect of Atremorine on MPTP parkinsonian mouse model. In addition to behavioral analysis, nigrostriatal dopaminergic neurons and inflammation biomarkers were directly quantified in the affected brain regions by specific antibody-antigen-binding methods. The affected neuronal populations and behavioural alterations induced by MPTP were significantly impaired in mice when treated with Atremorine-rich diet. Differences in the Atremorine content in diet induced some degrees of neuropathological and behavior therapeutical improvement, based on the progressive beneficial effects observed in nigro-striatal dopaminergic neurons of MPTPinduced mice. Data demonstrated that Atremorine promotes neuroprotection and behavior recovery in the injured MTPT-mouse brain by modulating the expression levels of tyrosine hydroxylase, glial proteins, apoptosis and endogenous dopamine and neuromelanin concentrations, probably the key to recover the basal ganglia function.
Export Options
About this article
Cite this article as:
Carrera Ivan*, Fernandez-Novoa Lucia, Sampedro Carolina and Cacabelos Ramon, Neuroprotective Effect of Atremorine in an Experimental Model of Parkinson’s Disease, Current Pharmaceutical Design 2017; 23 (18) . https://dx.doi.org/10.2174/1381612823666170210143530
DOI https://dx.doi.org/10.2174/1381612823666170210143530 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Trends in Patents of Enzymatic Biomarkers for Early Detection of Bacteria
Recent Patents on Biomarkers Exploring the Abnormal Signal Transduction Mediated Internet Addiction and Gaming Disorders
Current Signal Transduction Therapy Signal Transduction Pathways and Transcription Factors as Therapeutic Targets in Inflammatory Disease: Towards Innovative Antirheumatic Therapy
Current Pharmaceutical Design Sleep-Wake Patterns and Cognition of Older Adults with Amnestic Mild Cognitive Impairment (aMCI): A Comparison with Cognitively Healthy Adults and Moderate Alzheimer’s Disease Patients
Current Alzheimer Research Dorsal Stream Dysfunction in Children. A Review and an Approach to Diagnosis and Management
Current Pediatric Reviews Structure-Based Design, Synthesis and Molecular Modeling Studies of Thiazolyl Urea Derivatives as Novel Anti-Parkinsonian Agents
Medicinal Chemistry Targeting the Nogo-A Signalling Pathway to Promote Recovery Following Acute CNS Injury
Current Pharmaceutical Design Drivers’ Visual Scanning Impairment Under the Influences of Alcohol and Distraction: A Literature Review
Current Drug Abuse Reviews Significance of and Challenges in Regulating Endocrine Disruptors – How Regulators and Industry Can Conquer?
Endocrine, Metabolic & Immune Disorders - Drug Targets Link of COVID-19 and Neurodegenerative Disorders
CNS & Neurological Disorders - Drug Targets The Role of Lipids and Membranes in the Pathogenesis of Alzheimer's Disease: A Comprehensive View
Current Alzheimer Research The Role of Neurophysiological Biomarkers in Obsessive-Compulsive Disorder
Current Medicinal Chemistry Advances in Electrolytes for High Capacity Rechargeable Lithium-Sulphur Batteries
Current Smart Materials (Discontinued) Signal-Dependent Noise Induces Muscle Co-Contraction to Achieve Required Movement Accuracy: A Simulation Study with an Optimal Control
Current Bioinformatics Protein Kinases and their Modulation in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Botulinum Toxin: A Successful Therapeutic Protein
Current Medicinal Chemistry Structure-Based β-Secretase (BACE1) Inhibitors
Current Pharmaceutical Design Recent Progress in Gene Therapy for Parkinson’s Disease
Current Molecular Medicine Stimulus-feature Specific Modulation of the Visual Processing by Audiovisual Intermodal Orientation of Attention
Neuroscience and Biomedical Engineering (Discontinued) New Pharmacological Perspectives and Therapeutic Potential of PPAR-γ Agonists
Current Pharmaceutical Design